Guidelines in Practice | Cardiology | October 2026
Individualising antiplatelet selection, duration and de-escalation to balance thrombotic protection against bleeding risk
Introduction
Antiplatelet therapy remains fundamental to the management of acute coronary syndromes (ACS) and chronic coronary disease (CCD). However, contemporary treatment has evolved beyond uniform dual antiplatelet therapy (DAPT) regimens towards individualised strategies informed by thrombotic risk, bleeding risk, coronary anatomy, procedural complexity and patient-specific factors.
The 2026 American Heart Association (AHA) Scientific Statement, Multidisciplinary Approach to Antiplatelet Management in Coronary Syndromes, reviews contemporary evidence and highlights the importance of multidisciplinary antithrombotic stewardship.
The statement builds on the 2023 ACC/AHA guideline for chronic coronary disease and the 2025 ACC/AHA guideline for acute coronary syndromes. It is not a replacement clinical practice guideline; rather, it provides a framework for translating existing recommendations and evolving evidence into safer, more personalised clinical care.
Its central message is that antiplatelet management should deliver the appropriate treatment, at the appropriate intensity, for the appropriate duration, with coordinated reassessment throughout the patient's care.
1. Antiplatelet Management: Recommendations at a Glance
The following table summarises the principal guideline recommendations discussed in the statement.
| Clinical scenario | Recommended antiplatelet strategy | Key considerations |
|---|---|---|
| CCD without recent ACS | Single antiplatelet therapy, usually aspirin 75–100 mg daily | Long-term secondary prevention |
| Elective PCI for CCD | Aspirin + clopidogrel for 6 months, followed by SAPT | Standard approach |
| ACS without high bleeding risk | Aspirin + P2Y12 inhibitor for at least 12 months | Default DAPT duration |
| ACS undergoing PCI | Aspirin + prasugrel or ticagrelor preferred | Clopidogrel when preferred agents cannot be used |
| Selected PCI patients | Shorter DAPT, generally 1–3 months, followed by P2Y12 monotherapy | Individualise according to bleeding and thrombotic risk |
| PCI with an indication for oral anticoagulation | Triple therapy for approximately 1–4 weeks, then OAC + clopidogrel | Avoid unnecessarily prolonged triple therapy |
| Selected CCD patients with high recurrent thrombotic risk | Aspirin 81 mg daily + rivaroxaban 2.5 mg twice daily | Only when bleeding risk is acceptable and therapeutic anticoagulation is not indicated |
| Previous MI with low bleeding risk | Extended DAPT beyond 12 months, potentially up to 3 years | May be reasonable in selected patients |
These strategies are not interchangeable. Treatment must account for the indication, timing of PCI, clinical presentation and evolving risk profile.
2. Choosing the Appropriate P2Y12 Inhibitor
Selection of a P2Y12 inhibitor depends on whether the patient has ACS or CCD, the revascularisation strategy, contraindications, bleeding risk and the feasibility of maintaining treatment.
In ACS patients undergoing PCI, prasugrel or ticagrelor is preferred over clopidogrel, provided there are no contraindications or other factors preventing their use.
Comparison of commonly used antiplatelet agents
| Feature | Clopidogrel | Prasugrel | Ticagrelor |
|---|---|---|---|
| Loading dose | 300–600 mg | 60 mg | 180 mg |
| Maintenance dose | 75 mg once daily | 10 mg once daily (standard dose) | 90 mg twice daily |
| Platelet inhibition | Irreversible | Irreversible | Reversible |
| Approximate onset after loading | 2–6 hours | 30 minutes | 30 minutes |
| Duration of effect | 5–10 days | 7–10 days | 3–5 days |
| Typical preoperative withdrawal in the statement | 5 days | 7 days | 5 days |
| Important contraindications | Active bleeding | Previous stroke/TIA; active bleeding | Previous intracranial haemorrhage; active bleeding |
| Relative potency | Lower | Higher | Higher |
Prasugrel dosing requires particular attention in older patients and those with low body weight. The standard 10 mg maintenance dose should not be applied indiscriminately to these groups.
Clopidogrel remains an important option when more potent agents are contraindicated, unavailable, poorly tolerated or difficult to maintain because of treatment-access barriers.
Role of pharmacogenomics and platelet function testing
Clopidogrel requires metabolic activation, particularly through CYP2C19 pathways. Reduced-function variants may contribute to inadequate platelet inhibition.
The statement does not recommend routine pharmacogenomic or platelet function testing for every patient. Selective testing may be considered in patients with high ischaemic risk, recurrent thrombotic events despite adherence, suspected clopidogrel nonresponsiveness or complex antiplatelet decisions.
3. Duration of Dual Antiplatelet Therapy
DAPT duration remains one of the most important decisions following ACS or coronary intervention.
The 2026 statement emphasises that shorter regimens can reduce bleeding in appropriately selected patients, but the evidence should not be extrapolated indiscriminately to those at high thrombotic risk.
Standard versus shortened DAPT
| Strategy | Typical setting | Clinical considerations |
|---|---|---|
| 6 months DAPT | Elective PCI for CCD | Standard guideline-recommended duration |
| At least 12 months DAPT | ACS without high bleeding risk | Default strategy |
| 1–3 months DAPT followed by P2Y12 monotherapy | Selected PCI patients | Bleeding reduction while maintaining antithrombotic protection |
| De-escalation after 1 month | Selected ACS patients undergoing PCI | Switch from prasugrel/ticagrelor to clopidogrel |
| Extended DAPT beyond 12 months | Selected patients with previous MI | Consider when recurrent thrombotic risk outweighs bleeding risk |
Interpreting the evidence for shortened DAPT
Randomised trials and meta-analyses have generally demonstrated that shorter DAPT regimens followed by monotherapy can reduce bleeding without a significant increase in composite thrombotic outcomes in selected populations.
However, the statement identifies several important limitations:
- Many shortened-DAPT trials were smaller and had fewer thrombotic events than originally anticipated.
- Several enrolled relatively low-thrombotic-risk populations.
- Some studies included substantial East Asian populations, potentially affecting the generalisability of bleeding results.
- Reductions in bleeding were not consistently driven by major bleeding alone.
Consequently, the statement urges caution when considering abbreviated DAPT for patients with left main coronary stenting, multiple layers of stents or other complex coronary features.
4. Assessing Thrombotic and Bleeding Risk
Treatment decisions should integrate patient characteristics, coronary anatomy, procedural factors and the anticipated consequences of bleeding or thrombosis.
| Thrombotic risk considerations | Bleeding risk considerations |
|---|---|
| ACS presentation | Previous major bleeding |
| Complex PCI | Anaemia |
| Left main stenting | Thrombocytopenia |
| Multiple stents or stent layers | Renal or hepatic dysfunction |
| Previous thrombotic events | Advanced age or frailty |
| Diffuse coronary or polyvascular disease | Concomitant anticoagulant therapy |
| Suspected inadequate antiplatelet response | Interacting medicines, including NSAIDs |
Risk assessment tools discussed in the statement include PRECISE-DAPT, the DAPT Score, Academic Research Consortium High Bleeding Risk (ARC-HBR) criteria and the GRACE score.
These tools should support clinical judgement rather than replace it. No single score adequately captures every patient-specific or procedural factor.
5. DAPT De-escalation: Reducing Bleeding Risk
De-escalation refers to reducing the intensity of antiplatelet treatment when continued potent therapy is no longer necessary or when bleeding risk becomes more important.
Three strategies are highlighted.
Switching to clopidogrel: In selected ACS patients undergoing PCI, switching from prasugrel or ticagrelor to clopidogrel after one month may be reasonable to reduce bleeding risk.
Ticagrelor monotherapy: Patients who have tolerated DAPT with ticagrelor may transition to ticagrelor monotherapy at least one month after PCI to reduce bleeding risk.
Early single antiplatelet therapy: In selected patients undergoing PCI who are at high bleeding risk, transition to SAPT after one month may be considered.
These are alternative strategies, not sequential treatment steps. Selection depends on clinical context, treatment tolerance and the balance between ischaemic and bleeding risks.
Switching between P2Y12 inhibitors also requires attention to the pharmacological properties of each agent, including onset, offset, timing and potential need for a loading dose.
6. Patients Requiring Antiplatelet Therapy and Oral Anticoagulation
Patients who require oral anticoagulation in addition to antiplatelet therapy represent a particularly high-risk group because of the combined risks of thrombosis and bleeding.
Examples include patients with atrial fibrillation or another indication for anticoagulation who subsequently undergo PCI.
The statement emphasises avoiding unnecessarily prolonged triple therapy.
General antithrombotic sequence
| Treatment phase | Antithrombotic regimen |
|---|---|
| Initial period, generally 1–4 weeks | Aspirin + clopidogrel + oral anticoagulant |
| Following aspirin discontinuation | Clopidogrel + oral anticoagulant |
| Long-term, when appropriate | Oral anticoagulant alone |
The timing of transitions should be individualised according to the indication for anticoagulation, ACS versus CCD presentation, coronary thrombotic risk and bleeding risk.
Clopidogrel is generally the preferred P2Y12 inhibitor when combined with oral anticoagulation.
The statement also highlights the importance of prescribing explicit aspirin stop dates, reassessing the need for combination therapy and using medication reconciliation to prevent unintended continuation of triple therapy.
7. Perioperative Antiplatelet Management
Patients with coronary stents frequently require subsequent cardiac or non-cardiac surgery. Perioperative decisions must balance the danger of stent thrombosis against procedure-related bleeding.
The statement recommends coordinated planning involving cardiology, surgery and anaesthesia.
Timing of elective surgery after PCI
| Clinical scenario | Timing discussed in the statement |
|---|---|
| PCI for CCD | Ideally delay moderate- or high-bleeding-risk elective surgery for 3–6 months |
| PCI for ACS | Ideally delay elective surgery for at least 12 months |
These are planning principles, not absolute rules for every procedure. The urgency of surgery and the specific coronary and procedural risks remain important.
P2Y12 inhibitor interruption
| Agent | Typical withdrawal before surgery |
|---|---|
| Clopidogrel | 5 days |
| Ticagrelor | 5 days |
| Prasugrel | 7 days |
Aspirin is generally continued when appropriate, particularly for cardiac and vascular procedures. Complete antiplatelet cessation may be required for procedures where bleeding could have catastrophic consequences.
For selected patients with very high thrombotic risk who cannot continue oral P2Y12 therapy, intravenous cangrelor bridging may be considered under specialist supervision.
Restarting therapy
Antiplatelet therapy should generally be restarted once haemostasis is secure.
The statement discusses restarting DAPT on postoperative day zero in suitable nonbleeding patients and generally within 24–72 hours when clinically appropriate.
Neuraxial procedures require additional precautions; the statement specifies avoiding antiplatelet reinitiation for at least 24 hours after catheter removal.
8. Long-Term Prevention in Chronic Coronary Disease
Although single antiplatelet therapy is the usual long-term approach for many patients with CCD, selected individuals remain at increased risk of recurrent thrombotic events.
In patients with high recurrent thrombotic risk and low-to-moderate bleeding risk, dual-pathway inhibition may be reasonable.
Aspirin 81 mg once daily
Rivaroxaban 2.5 mg twice daily
This strategy aims to reduce major adverse cardiovascular events.
It should not be used routinely in all patients with CCD and is not a substitute for therapeutic-dose anticoagulation in patients who require anticoagulation for another indication.
Patients with peripheral arterial disease or diffuse polyvascular disease may warrant particular consideration, while bleeding risk must be reassessed carefully.
9. Antiplatelet Stewardship: The Central Message of the Statement
A major contribution of the 2026 AHA statement is its emphasis on multidisciplinary antithrombotic stewardship.
The concept extends beyond selecting the correct drug. It involves ensuring that antiplatelet treatment remains appropriate, accessible, safe and effective throughout hospitalisation, discharge and long-term follow-up.
Five priorities of antiplatelet stewardship
| Priority | Practical implementation |
|---|---|
| Evidence-based prescribing | Correct agent, indication, dose and duration |
| Risk stratification | Assess bleeding and thrombotic risks before and during treatment |
| Safe transitions | Medication reconciliation at admission, discharge and transfer |
| Monitoring and feedback | Review adherence, bleeding, recurrent events and treatment stop dates |
| Shared decision-making | Incorporate patient preferences, affordability and treatment feasibility |
Multidisciplinary responsibilities
| Team member | Principal responsibilities |
|---|---|
| Cardiologist | Antiplatelet selection, PCI-related thrombotic risk and treatment duration |
| Pharmacist | Medication reconciliation, interactions, dosing, switching and adherence |
| Nursing team | Patient education, monitoring, adverse-event recognition and follow-up |
| Surgeon and anaesthetist | Perioperative interruption and restarting strategies |
| Primary care team | Long-term monitoring and treatment continuity |
| Case manager/social worker | Medication access, affordability and social barriers |
| Clinical informatics team | Electronic alerts, treatment-duration tracking and quality monitoring |
The statement highlights the importance of structured discharge processes, particularly because unintended antiplatelet discontinuation can expose patients to avoidable thrombotic complications.
Every discharge plan should clearly communicate the antithrombotic regimen, its intended duration, any planned treatment changes and the responsible follow-up clinician.
10. Clinical Algorithms
The following algorithms translate the clinical recommendations discussed in the statement into practical decision pathways. They are educational syntheses of the source, not formally validated AHA algorithms.
Algorithm 1 — Antiplatelet Strategy Following ACS or Elective PCI
Patient with ACS or CCD undergoing PCI
Assess presentation, bleeding risk, thrombotic risk and need for OAC
Elective PCI for CCD
Aspirin + clopidogrel
6 months DAPT
SAPT
ACS
Aspirin + P2Y12 inhibitor
≥12 months DAPT (default)
Reassess for SAPT
Selected patients: Consider shorter DAPT
1–3 months followed by P2Y12 monotherapy when supported by the clinical scenario and bleeding/thrombotic risk.
Patients requiring OAC follow a separate combination-antithrombotic pathway.
Algorithm 2 — Antithrombotic Management When Oral Anticoagulation Is Required
PCI patient requiring long-term OAC
INITIAL PERIOD · GENERALLY 1–4 WEEKS
Aspirin + Clopidogrel + OAC
DISCONTINUE ASPIRIN AT PLANNED TIME
Clopidogrel + OAC
LONG-TERM, WHEN APPROPRIATE
OAC Monotherapy
The duration of each phase depends on ACS versus CCD, PCI characteristics, bleeding risk and the indication for anticoagulation.